Last reviewed · How we verify

NeisVac C vaccine (12mth) — Competitive Intelligence Brief

NeisVac C vaccine (12mth) (NeisVac C vaccine (12mth)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Meningococcal conjugate vaccine. Area: Immunology / Infectious Disease.

marketed Meningococcal conjugate vaccine Neisseria meningitidis serogroup C polysaccharide capsule Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

NeisVac C vaccine (12mth) (NeisVac C vaccine (12mth)) — University of British Columbia. NeisVac C is a conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C polysaccharide capsule.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NeisVac C vaccine (12mth) TARGET NeisVac C vaccine (12mth) University of British Columbia marketed Meningococcal conjugate vaccine Neisseria meningitidis serogroup C polysaccharide capsule
Prevenar and Meningitec Prevenar and Meningitec Wyeth is now a wholly owned subsidiary of Pfizer marketed Conjugate vaccine Streptococcus pneumoniae polysaccharide capsule (Prevenar); Neisseria meningitidis serogroup C polysaccharide capsule (Meningitec)
NeisVac-C® NeisVac-C® Merck Sharp & Dohme LLC marketed Meningococcal conjugate vaccine Neisseria meningitidis serogroup C polysaccharide capsule
Meningococcal C Meningococcal C Wyeth is now a wholly owned subsidiary of Pfizer marketed Conjugate vaccine Neisseria meningitidis serogroup C polysaccharide capsule
Meningitec® Meningitec® GlaxoSmithKline marketed Conjugate vaccine Neisseria meningitidis serogroup C polysaccharide capsule
MCC-CRM MCC-CRM MCM Vaccines B.V. phase 3 Conjugate vaccine Neisseria meningitidis serogroup C polysaccharide capsule
Neis-Vac-C Neis-Vac-C GlaxoSmithKline phase 3 Conjugate vaccine Neisseria meningitidis serogroup C polysaccharide capsule

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Meningococcal conjugate vaccine class)

  1. GlaxoSmithKline · 8 drugs in this class
  2. CanSino Biologics Inc. · 3 drugs in this class
  3. Beijing Minhai Biotechnology Co., Ltd · 2 drugs in this class
  4. Novartis · 1 drug in this class
  5. Pfizer · 1 drug in this class
  6. University of British Columbia · 1 drug in this class
  7. International Vaccine Institute · 1 drug in this class
  8. Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NeisVac C vaccine (12mth) — Competitive Intelligence Brief. https://druglandscape.com/ci/neisvac-c-vaccine-12mth. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: